Table 2.
Group 1 (n = 29) | Group 2 (n = 31) | p | |
---|---|---|---|
Age (years) | 65.03 ± 8.56 | 66.67 ± 7.62 | 0.435 |
Male/Female | 10/19 | 8/23 | 0.464 |
Comorbidities: | |||
Cardiovascular diseases | 26 (89.6%) | 28 (90.3%) | 1.000 |
Endocrine diseases | 8 (27.6%) | 7 (22.6%) | 0.881 |
Metabolic diseases | 8 (27.6%) | 13 (41.9%) | 0.372 |
Gastrointestinal diseases | 5 (17.2%) | 3 (9.6%) | 0.465 |
Benign prostate hyperplasia | 3 (10.3%) | 2 (6.4%) | 0.666 |
Psychiatric diseases | 3 (10.3%) | 2 (6.4%) | 0.666 |
Osteoporosis | 4 (13.8%) | 6 (19.3%) | 0.732 |
Knee OA duration (years) | 6.57 ± 5.30 | 4.88 ± 3.53 | 0.353 |
Radiological score distribution | |||
Kellgren-Laurence grade 2 | 19 (65.5%) | 25 (80.6%) | 0.302 |
Kellgren-Laurence grade 3 | 10 (34.5%) | 6 (19.3%) | |
Other OA | |||
Hip OA | 11 (37.9%) | 11 (35.5%) | 0.844 |
Shoulder OA | 2 (6.9%) | 4 (12.9%) | 0.672 |
Ankle OA | 2 (6.9%) | 1 (3.2%) | 0.606 |